U.S. COMPANY FILING
ALNYLAM PHARMACEUTICALS, INC. — Form 8-K filed 2026-01-12
Filing text preview
On January 11, 2026, Alnylam announced its new five-year strategy 'Alnylam 2030' and preliminary Q4 and full-year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO. The company also provided 2026 product and pipeline goals and full-year 2026 revenue guidance. Results are unaudited and subject to adjustment; final results will be reported in February 2026.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record